Respiratory Clinical Trials in the UK (2026): Asthma, COPD, Cystic Fibrosis and Sleep Apnoea
Respiratory conditions are among the most common reasons for NHS hospital admissions. Clinical trials are driving real advances — biologic therapies for severe asthma, gene therapy for cystic fibrosis, and novel anti-inflammatory drugs for COPD are all in active UK trials.
Severe Asthma: The Biologics Revolution
For the millions of UK asthma patients whose condition is well-controlled with standard inhalers, the treatment landscape is mature. But for the significant minority with severe, uncontrolled asthma, biologic drugs have been transformative. These targeted therapies block specific immune molecules (IL-5, IL-4/IL-13, IgE) that drive airway inflammation. UK trials continue to test new biologics, biosimilar versions for broader access, and combination approaches for patients who do not respond to a single agent.
COPD: New Approaches to an Old Problem
COPD clinical trials are exploring novel anti-inflammatory drugs that go beyond current bronchodilator and steroid combinations. Trials target specific inflammatory pathways, stem cell therapy for lung tissue repair, and lung volume reduction techniques. A major focus is reducing exacerbations — the dangerous flare-ups that cause hospitalisation and accelerate lung function decline.
Cystic Fibrosis: Gene Therapy and Beyond
While CFTR modulators have transformed cystic fibrosis care for patients with specific mutations, gene therapy aims to treat the underlying cause regardless of mutation type. UK research centres, particularly the Oxford Gene Therapy Consortium, are at the forefront of this work. Trials are testing viral and non-viral gene delivery methods, with promising early results. For patients who cannot take CFTR modulators, gene therapy trials offer genuine hope.
Sleep Apnoea: Beyond CPAP
Obstructive sleep apnoea affects an estimated 1.5 million UK adults, yet many remain undiagnosed. While CPAP therapy remains the standard treatment, trials are testing alternatives including hypoglossal nerve stimulation (a surgically implanted device that keeps the airway open during sleep), novel medications, and digital monitoring tools that improve CPAP adherence.